ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Lonza plans to spend over $500 million to build a commercial-scale fill-and-finish facility for biologic drugs at a site in Stein, Switzerland. The drug services company launched its dosage-form drug business in Basel, Switzerland, in 2016, for injectable and infusible versions of antibodies, drug conjugates, peptides, and small molecules, mostly at clinical scale. Lonza has since added dosage-form services at its plants in Visp, Switzerland, and Guangzhou, China. It acquired the Stein site from Novartis in 2019.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter